激肽释放酶原的一种前清蛋白激活剂。3. 人激肽释放酶原转化为激肽释放酶后出现对人中性粒细胞的趋化活性。
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.
作者信息
Kaplan A P, Kay A B, Austen K F
出版信息
J Exp Med. 1972 Jan;135(1):81-97. doi: 10.1084/jem.135.1.81.
Abstract
Human plasma kallikrein has been shown to directly and selectively attract human neutrophils from a mixed leukocyte population. The capacity of plasma kallikrein to be chemotactic and to generate the nonapeptide bradykinin was maintained during progressive purification. While neither highly purified prekallikrein nor the prealbumin Hageman factor fragments were chemotactic alone, their interaction so as to convert prekallikrein to kallikrein yielded both chemotactic and kinin-generating activity. Both functions of kallikrein were inhibited by treatment with diisopropyl fluorophosphate, indicating an essential role for the active site of the enzyme in the expression of its chemotactic activity.
摘要
人血浆激肽释放酶已被证明能直接且选择性地从混合白细胞群体中吸引人类中性粒细胞。在逐步纯化过程中，血浆激肽释放酶的趋化能力以及生成九肽缓激肽的能力得以保留。虽然高度纯化的前激肽释放酶和前白蛋白哈格曼因子片段单独都没有趋化作用，但它们相互作用使前激肽释放酶转化为激肽释放酶后，产生了趋化活性和激肽生成活性。用二异丙基氟磷酸处理可抑制激肽释放酶的这两种功能，表明该酶的活性位点在其趋化活性表达中起关键作用。
相似文献
1
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.激肽释放酶原的一种前清蛋白激活剂。3. 人激肽释放酶原转化为激肽释放酶后出现对人中性粒细胞的趋化活性。
J Exp Med. 1972 Jan;135(1):81-97. doi: 10.1084/jem.135.1.81.
2
The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator.人血浆的纤维蛋白溶解途径。II. 通过纤溶酶原激活剂的激活产生趋化活性。
J Clin Invest. 1973 Oct;52(10):2591-5. doi: 10.1172/JCI107451.
3
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.激肽释放酶原的前清蛋白激活剂。II. 用纤溶酶消化活性Hageman因子以获得激肽释放酶原激活剂
J Exp Med. 1971 Apr 1;133(4):696-712. doi: 10.1084/jem.133.4.696.
4
Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.弗莱彻因子缺乏症。由于缺乏前激肽释放酶导致哈格曼因子激活速率降低，伴有凝血、纤维蛋白溶解、趋化活性和激肽生成异常。
J Clin Invest. 1974 Feb;53(2):622-33. doi: 10.1172/JCI107597.
5
Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.通过Hageman因子依赖性地将血浆前激肽释放酶转化为激肽释放酶来启动血浆肾素原激活。
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5914-8. doi: 10.1073/pnas.76.11.5914.
6
Activation mechanism of human Hageman factor-plasma kallikrein-kinin system by Vibrio vulnificus metalloprotease.创伤弧菌金属蛋白酶激活人凝血因子 XII - 血浆激肽释放酶 - 激肽系统的机制
FEBS Lett. 1992 Aug 24;308(3):315-9. doi: 10.1016/0014-5793(92)81301-2.
7
8
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate.人血浆前激肽释放酶。关于其被活化因子XII激活以及被二异丙基氟磷酸酯灭活的研究。
Biochemistry. 1980 Mar 18;19(6):1151-60. doi: 10.1021/bi00547a018.
9
10
[Plasma kallikrein: new functions].[血浆激肽释放酶：新功能]
Biokhimiia. 1976 Aug;41(8):1347-51.
引用本文的文献
1
Alzheimer's Disease: In Vitro and In Vivo Evidence of Activation of the Plasma Bradykinin-Forming Cascade and Implications for Therapy.阿尔茨海默病：血浆缓激肽形成级联激活的体外和体内证据及其治疗意义。
Cells. 2024 Dec 10;13(24):2039. doi: 10.3390/cells13242039.
2
C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis.C1 抑制剂缺乏增强了接触途径介导的凝血和静脉血栓形成。
Blood. 2023 May 11;141(19):2390-2401. doi: 10.1182/blood.2022018849.
3
Plasma kallikrein predicts primary graft dysfunction after heart transplant.血浆激肽释放酶可预测心脏移植后的原发性移植物功能障碍。
J Heart Lung Transplant. 2021 Oct;40(10):1199-1211. doi: 10.1016/j.healun.2021.07.001. Epub 2021 Jul 10.
4
Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI.接触激活系统与因子XI的细胞受体和辅助因子相互作用
Front Med (Lausanne). 2018 Mar 21;5:66. doi: 10.3389/fmed.2018.00066. eCollection 2018.
5
A review on chemical-induced inflammatory bowel disease models in rodents.化学诱导的啮齿动物炎症性肠病模型研究综述。
Korean J Physiol Pharmacol. 2014 Aug;18(4):279-88. doi: 10.4196/kjpp.2014.18.4.279. Epub 2014 Aug 13.
6
Monitoring of immunotherapy with cytokines or monoclonal antibodies.细胞因子或单克隆抗体免疫治疗监测。
Cytotechnology. 1995 Jan;18(1-2):93-106. doi: 10.1007/BF00744324.
7
PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis.PF-04886847（一种血浆激肽释放酶抑制剂）可减轻脂多糖（LPS）诱导的大鼠脓毒症模型中的炎症介质及凝血激活。
Cardiovasc Hematol Agents Med Chem. 2012 Jun;10(2):154-66. doi: 10.2174/187152512800388939.
8
Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor.新型高亲和力和特异性血浆激肽释放酶抑制剂的生化特性分析。
Br J Pharmacol. 2011 Apr;162(7):1639-49. doi: 10.1111/j.1476-5381.2010.01170.x.
9
Human plasma kallikrein-kinin system: physiological and biochemical parameters.人血浆激肽释放酶-激肽系统：生理和生化参数
Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):234-50. doi: 10.2174/187152509789105444.
10
Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.脂多糖（LPS）处理的内皮细胞中脯氨酰羧肽酶（PRCP）的上调促进炎症反应。
J Inflamm (Lond). 2009 Jan 27;6:3. doi: 10.1186/1476-9255-6-3.
本文引用的文献
1
Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin.缓激肽是一种由蛇毒和胰蛋白酶从血浆球蛋白中释放出来的具有降血压作用和平滑肌刺激作用的因子。
Am J Physiol. 1949 Feb;156(2):261-73. doi: 10.1152/ajplegacy.1949.156.2.261.
2
Stoichiometric inhibition of chymotrypsin.胰凝乳蛋白酶的化学计量抑制作用。
Adv Enzymol Relat Subj Biochem. 1952;13:321-43. doi: 10.1002/9780470122587.ch8.
3
Bradykinin.缓激肽
Nature. 1961 Nov 18;192:596-9. doi: 10.1038/192596a0.
4
THE INFLAMMATORY PROCESS IN ACUTE GOUTY ARTHRITIS. I. ACTIVATION OF HAGEMAN FACTOR BY SODIUM URATE CRYSTALS.急性痛风性关节炎中的炎症过程。I. 尿酸钠晶体对激活因子的激活作用
J Lab Clin Med. 1965 Feb;65:307-15.
5
AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.血液凝固机制中的酶级联反应及其作为生物化学放大器的功能。
Nature. 1964 May 2;202:498-9. doi: 10.1038/202498a0.
6
7
Role of Hageman factor in the activation of vasodilator activity in human plasma.哈格曼因子在激活人血浆中血管舒张活性方面的作用。
Nature. 1961 Oct 14;192:180-1. doi: 10.1038/192180a0.
8
The nature of the kallidins released from human plasma by kallikreins and other enzymes.激肽释放酶及其他酶从人血浆中释放出的胰激肽的性质。
Ann N Y Acad Sci. 1963 Feb 4;104:91-107. doi: 10.1111/j.1749-6632.1963.tb17655.x.
9
Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma.从人血浆中分离血浆促凝血酶原激酶前体（PTA）和哈格曼因子（HF）。
Proc Soc Exp Biol Med. 1960 Dec;105:453-5. doi: 10.3181/00379727-105-26138.
10
Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent.关于哈格曼因子作用的研究：活化的哈格曼因子反过来激活血浆促凝血酶原激酶前体的证据。
J Clin Invest. 1961 May;40(5):803-19. doi: 10.1172/JCI104314.
Zotero 插件